Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly insulin icodec vs once-daily insulin glargine U100 in adults with type 1 diabetes
2024-519945-31-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised trial in diabetes mellitus type 1 (T1D) comparing Once-weekly insulin icodec + insulin aspart with Once-daily insulin glargine U100 + insulin aspart (2 arms). Primary endpoint: Change in HbA1c. Planned start Aug 2025; status: authorised.
02
Drugs
insulin aspartinsulin glargine
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-519945-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519945-31-00.